|
PureTech Health PLC on Wednesday said that it had advanced LYT-310, an oral form of cannabidiol (CBD) prodrug toward clinical studies.
The Boston, United States-based clinical-stage biotherapeutics company said LYT-310 demonstrated a three to fourfold increase in oral bioavailability - the extent of the drug dosage that reaches the therapeutic site of action - compared to unmodified CBD, according to PureTech’s preclinical model.
LYT-310 could expand the therapeutic applications of CBD across a wider age range (higher doses of CBD are required to achieve a therapeutic effect in adolescents and adults) and both rare and common forms of epilepsy, as well as other central nervous system disorders, the company said.
PureTech said LYT-310 is produced using the company’s synthetic lymphatic-targeting chemistry platform called Glyph. It enables more effective oral administration of small molecules.
‘The nomination of LYT-310 is an exciting expansion of PureTech’s Glyph technology,’ PureTech Vice President Daniel Bonner said.
The technology allows PureTech to ‘unlock the therapeutic potential of a range of molecules with validated efficacy whose development has been limited by first pass metabolism by the liver,’ Bonner said.
PureTech shares closed up 2.3% at 277.55 pence per share on Monday afternoon in London.
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
